<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066478</url>
  </required_header>
  <id_info>
    <org_study_id>2017DHEA</org_study_id>
    <nct_id>NCT04066478</nct_id>
  </id_info>
  <brief_title>Does DHEA IVF Outcomes in Poor Responders?</brief_title>
  <acronym>DHEA</acronym>
  <official_title>Does Dehydroepiandrosterone (DHEA) Improve IVF Outcomes in Poor Responders? A Randomised, Double-blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Homerton University Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Homerton University Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a RCT to examine whether DHEA is capable of improving results for poor
      responders to ovarian stimulation during IVF treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Poor responders to ovarian stimulation for IVF may be either predicted or evidenced from
      previous treatment. The ESHRE criteria for poor responders will be used to select candidates
      for this trial. A power calculation determined that 200 subjects should be recruited to each
      arm to receive either DHEA or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, double-blind, placebo controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rates</measure>
    <time_frame>at 6-8 weeks gestation</time_frame>
    <description>ultrasound confirmation of a foetus with a heartbeat</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Poor Response to Ovulation Induction</condition>
  <arm_group>
    <arm_group_label>Teatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comaprator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone</intervention_name>
    <description>75mg Dehydroepiandrosterone daily</description>
    <arm_group_label>Teatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Comaprator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 40 years

          -  Markers for poor ovarian reserve (AMH &lt;7 pmol/L(&lt;1.1 ng/ml) and/or AFC&lt; 7)

          -  Previous poor response to ovarian stimulation ( ≤3 oocytes with a conventional
             stimulation protocol)

        Exclusion Criteria:

          -  Women &gt; 42 years

          -  Women with premature ovarian failure / premature menopause (FSH&gt;40 U/L). Women already
             taking DHEA.

          -  Patients with a known allergy to the trial drug or any of the active ingredients in
             the placebo.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roy Homburg</last_name>
    <phone>02085105211</phone>
    <email>royhomburg@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hassina Fureed</last_name>
    <phone>02085105993</phone>
    <email>h.furreed@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Homerton Fertility Centre</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassina Furreed</last_name>
      <phone>02085105211</phone>
      <email>h.fureed@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Roy Homburg, FROG</last_name>
      <phone>02085105211</phone>
      <email>royhomburg@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

